Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yinhu Qingwen Granula for Severe COVID-19
NCT04310865Phase 3Suspended
- Start
- Nov 2021
- Primary completion
- Dec 2022
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Yinhu Qingwen Granula in coronavirus disease 2019 (COVID-19) (2 arms). Primary endpoint: Changes in the ratio of PaO2 to FiO2 from baseline at Day 10. Started Nov 2021; status: suspended.
02
Drugs
Yinhu Qingwen Granula
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04310865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04310865.